According to Zacks, “PhaseBio Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. The company’s product consists of PB2452, a novel reversal agent for the antiplatelet drug ticagrelor and PB1046, a once-weekly fusion protein for the treatment of pulmonary arterial hypertension, which are in clinical stage. PhaseBio Pharmaceuticals Inc. is based in Malvern, United States. “
Separately, Citigroup set a $27.00 price objective on PhaseBio Pharmaceuticals and gave the company a buy rating in a research report on Friday, May 24th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of Buy and an average price target of $17.75.
Shares of PhaseBio Pharmaceuticals stock opened at $11.22 on Thursday. The firm has a market capitalization of $274.87 million and a PE ratio of -2.50. The stock has a fifty day simple moving average of $11.79. The company has a current ratio of 14.24, a quick ratio of 14.24 and a debt-to-equity ratio of 0.19. PhaseBio Pharmaceuticals has a 12 month low of $2.55 and a 12 month high of $16.65.
PhaseBio Pharmaceuticals (NASDAQ:PHAS) last issued its earnings results on Thursday, May 9th. The company reported ($0.30) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.44) by $0.14. The business had revenue of $0.65 million during the quarter, compared to analyst estimates of $0.12 million. As a group, research analysts anticipate that PhaseBio Pharmaceuticals will post -1.47 earnings per share for the current fiscal year.
In related news, Director Clay Thorp sold 2,908 shares of PhaseBio Pharmaceuticals stock in a transaction on Monday, July 1st. The stock was sold at an average price of $14.00, for a total transaction of $40,712.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 17.00% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in PhaseBio Pharmaceuticals during the fourth quarter valued at $79,000. Millennium Management LLC acquired a new stake in PhaseBio Pharmaceuticals during the fourth quarter valued at $411,000. United Services Automobile Association acquired a new stake in PhaseBio Pharmaceuticals during the fourth quarter valued at $286,000. Tibra Equities Europe Ltd acquired a new stake in PhaseBio Pharmaceuticals during the first quarter valued at $217,000. Finally, Citigroup Inc. acquired a new stake in PhaseBio Pharmaceuticals during the fourth quarter valued at $351,000. 28.27% of the stock is owned by hedge funds and other institutional investors.
PhaseBio Pharmaceuticals Company Profile
PhaseBio Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery.
Recommended Story: Diversification
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PhaseBio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseBio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.